Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. p73 Is Required for pIgR Expression in the Respiratory Epithelium. Richmond BW, Du RH, Marshall C, Pietenpol J, Polosukhin VV, Blackwell TS (2018) Ann Am Thorac Soc 15(Supplement_4): S290
    › Primary publication · 30759000 (PubMed) · PMC6322007 (PubMed Central)
  2. p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton. Fuertes-Alvarez S, Maeso-Alonso L, Villoch-Fernandez J, Wildung M, Martin-Lopez M, Marshall C, Villena-Cortes AJ, Diez-Prieto I, Pietenpol JA, Tissir F, Lizé M, Marques MM, Marin MC (2018) Cell Death Dis 9(12): 1183
    › Primary publication · 30518789 (PubMed) · PMC6281643 (PubMed Central)
  3. p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. Santos Guasch GL, Beeler JS, Marshall CB, Shaver TM, Sheng Q, Johnson KN, Boyd KL, Venters BJ, Cook RS, Pietenpol JA (2018) iScience : 236-249
    › Primary publication · 30340069 (PubMed) · PMC6197761 (PubMed Central)
  4. Corrigendum to "Comparative Study of Exome Copy Number Variation Estimation Tools Using Array Comparative Genomic Hybridization as Control". Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, Shyr Y (2017) Biomed Res Int : 7409598
    › Primary publication · 28804721 (PubMed) · PMC5540237 (PubMed Central)
  5. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. Jovanović B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD (2017) BMC Cancer 17(1): 241
    › Primary publication · 28376728 (PubMed) · PMC5379658 (PubMed Central)
  6. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA (2017) Clin Cancer Res 23(15): 4035-4045
    › Primary publication · 28270498 (PubMed) · PMC5540799 (PubMed Central)
  7. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors. Cowen SD, Russell D, Dakin LA, Chen H, Larsen NA, Godin R, Throner S, Zheng X, Molina A, Wu J, Cheung T, Howard T, Garcia-Arenas R, Keen N, Pendleton CS, Pietenpol JA, Ferguson AD (2016) J Med Chem 59(24): 11079-11097
    › Primary publication · 28002961 (PubMed)
  8. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. Ludwik KA, Campbell JP, Li M, Li Y, Sandusky ZM, Pasic L, Sowder ME, Brenin DR, Pietenpol JA, O'Doherty GA, Lannigan DA (2016) Mol Cancer Ther 15(11): 2598-2608
    › Primary publication · 27528706 (PubMed) · PMC5807013 (PubMed Central)
  9. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA (2016) PLoS One 11(6): e0157368
    › Primary publication · 27310713 (PubMed) · PMC4911051 (PubMed Central)
  10. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA (2016) Cancer Res 76(16): 4850-60
    › Primary publication · 27231203 (PubMed) · PMC4987189 (PubMed Central)
  11. Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS (2016) BMC Cancer : 275
    › Primary publication · 27090641 (PubMed) · PMC4835864 (PubMed Central)
  12. p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. Marshall CB, Mays DJ, Beeler JS, Rosenbluth JM, Boyd KL, Santos Guasch GL, Shaver TM, Tang LJ, Liu Q, Shyr Y, Venters BJ, Magnuson MA, Pietenpol JA (2016) Cell Rep 14(10): 2289-300
    › Primary publication · 26947080 (PubMed) · PMC4794398 (PubMed Central)
  13. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS (2016) BMC Cancer : 143
    › Primary publication · 26908167 (PubMed) · PMC4763445 (PubMed Central)
  14. RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library. Guo Y, Zhao S, Sheng Q, Guo M, Lehmann B, Pietenpol J, Samuels DC, Shyr Y (2015) Biomed Res Int : 862130
    › Primary publication · 26543871 (PubMed) · PMC4620295 (PubMed Central)
  15. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM (2015) Cancer Discov 5(11): 1155-63
    › Primary publication · 26286086 (PubMed) · PMC4631701 (PubMed Central)
  16. Clinical implications of molecular heterogeneity in triple negative breast cancer. Lehmann BD, Pietenpol JA (2015) Breast : S36-40
    › Primary publication · 26253813 (PubMed) · PMC4641762 (PubMed Central)
  17. Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data. Zhang P, Samuels DC, Lehmann B, Stricker T, Pietenpol J, Shyr Y, Guo Y (2016) Brief Bioinform 17(2): 224-32
    › Primary publication · 26249222 (PubMed) · PMC5974936 (PubMed Central)
  18. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Lehmann BD, Pietenpol JA, Tan AR (2015) Am Soc Clin Oncol Educ Book : e31-9
    › Primary publication · 25993190 (PubMed)
  19. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D (2015) Oncotarget 6(25): 21353-68
    › Primary publication · 25972361 (PubMed) · PMC4673270 (PubMed Central)
  20. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D (2015) PLoS One 10(5): e0125482
    › Primary publication · 25965342 (PubMed) · PMC4428765 (PubMed Central)
  21. Detection of internal exon deletion with exon Del. Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y (2014) BMC Bioinformatics : 332
    › Primary publication · 25322818 (PubMed) · PMC4288651 (PubMed Central)
  22. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA (2014) Breast Cancer Res 16(4): 406
    › Primary publication · 25103565 (PubMed) · PMC4187324 (PubMed Central)
  23. Subtyping of triple-negative breast cancer: implications for therapy. Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA (2015) Cancer 121(1): 8-16
    › Primary publication · 25043972 (PubMed) · PMC4270831 (PubMed Central)
  24. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL (2014) Breast Cancer Res 16(4): R69
    › Primary publication · 24985072 (PubMed) · PMC4095685 (PubMed Central)
  25. Multi-perspective quality control of Illumina exome sequencing data using QC3. Guo Y, Zhao S, Sheng Q, Ye F, Li J, Lehmann B, Pietenpol J, Samuels DC, Shyr Y (2014) Genomics 103(5-6): 323-8
    › Primary publication · 24703969 (PubMed) · PMC5755963 (PubMed Central)
  26. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK (2014) Cancer Res 74(11): 3180-94
    › Primary publication · 24662921 (PubMed) · PMC4096808 (PubMed Central)
  27. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) Clin Cancer Res 20(4): 782-90
    › Primary publication · 24536073 (PubMed) · PMC3962777 (PubMed Central)
  28. Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes. Burgess EF, Ham AJ, Tabb DL, Billheimer D, Roth BJ, Chang SS, Cookson MS, Hinton TJ, Cheek KL, Hill S, Pietenpol JA (2008) Proteomics Clin Appl 2(9): 1223
    › Primary publication · 20107526 (PubMed) · PMC2811579 (PubMed Central)
  29. The jury is in: p73 is a tumor suppressor after all. Rosenbluth JM, Pietenpol JA (2008) Genes Dev 22(19): 2591-5
    › Primary publication · 18832062 (PubMed)
  30. Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1. Brown KA, Ham AJ, Clark CN, Meller N, Law BK, Chytil A, Cheng N, Pietenpol JA, Moses HL (2008) J Cell Biochem 105(2): 596-611
    › Primary publication · 18729074 (PubMed) · PMC2700048 (PubMed Central)
  31. A gene signature-based approach identifies mTOR as a regulator of p73. Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA (2008) Mol Cell Biol 28(19): 5951-64
    › Primary publication · 18678646 (PubMed) · PMC2547001 (PubMed Central)
  32. p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Perez CA, Ott J, Mays DJ, Pietenpol JA (2007) Oncogene 26(52): 7363-70
    › Primary publication · 17563751 (PubMed)
  33. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N (2007) Cancer Biol Ther 6(4): 561-70
    › Primary publication · 17495520 (PubMed) · PMC3395216 (PubMed Central)
  34. p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis. Schavolt KL, Pietenpol JA (2007) Oncogene 26(42): 6125-32
    › Primary publication · 17404570 (PubMed)
  35. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. Brown KA, Pietenpol JA, Moses HL (2007) J Cell Biochem 101(1): 9-33
    › Primary publication · 17340614 (PubMed)
  36. Transcriptional programs regulated by p63 in normal epithelium and tumors. Perez CA, Pietenpol JA (2007) Cell Cycle 6(3): 246-54
    › Primary publication · 17297308 (PubMed)
  37. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA (2006) Cancer Res 66(15): 7589-97
    › Primary publication · 16885358 (PubMed)
  38. The DNA binding activity of p53 displays reaction-diffusion kinetics. Hinow P, Rogers CE, Barbieri CE, Pietenpol JA, Kenworthy AK, DiBenedetto E (2006) Biophys J 91(1): 330-42
    › Primary publication · 16603489 (PubMed) · PMC1479054 (PubMed Central)
  39. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA (2006) Clin Cancer Res 12(5): 1570-6
    › Primary publication · 16533783 (PubMed)
  40. p63 and epithelial biology. Barbieri CE, Pietenpol JA (2006) Exp Cell Res 312(6): 695-706
    › Primary publication · 16406339 (PubMed)
  41. Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Hearnes JM, Mays DJ, Schavolt KL, Tang L, Jiang X, Pietenpol JA (2005) Mol Cell Biol 25(22): 10148-58
    › Primary publication · 16260627 (PubMed) · PMC1280257 (PubMed Central)
  42. p53 family members: similar biochemistry, different biology. Barbieri CE, Pietenpol JA (2005) Cancer Biol Ther 4(4): 419-20
    › Primary publication · 15908776 (PubMed)
  43. Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells. Van Dross R, Yao S, Asad S, Westlake G, Mays DJ, Barquero L, Duell S, Pietenpol JA, Browning PJ (2005) J Natl Cancer Inst 97(9): 656-66
    › Primary publication · 15870436 (PubMed)
  44. Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Westfall MD, Joyner AS, Barbieri CE, Livingstone M, Pietenpol JA (2005) Cell Cycle 4(5): 710-6
    › Primary publication · 15846104 (PubMed)
  45. Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. Maas K, Westfall M, Pietenpol J, Olsen NJ, Aune T (2005) Arthritis Rheum 52(4): 1047-57
    › Primary publication · 15818671 (PubMed)
  46. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA (2004) Laryngoscope 114(12): 2063-72
    › Primary publication · 15564824 (PubMed)
  47. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, Moses HL (2004) Breast Cancer Res 6(3): R215-31
    › Primary publication · 15084245 (PubMed) · PMC400675 (PubMed Central)
  48. p63: Molecular complexity in development and cancer. Westfall MD, Pietenpol JA (2004) Carcinogenesis 25(6): 857-64
    › Primary publication · 15033906 (PubMed)
  49. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL (2003) Cancer Res 63(21): 7113-21
    › Primary publication · 14612504 (PubMed)
  50. Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. Barbieri CE, Barton CE, Pietenpol JA (2003) J Biol Chem 278(51): 51408-14
    › Primary publication · 14555649 (PubMed)
  51. Combined modality management of breast cancer: development of predictive markers through proteomics. Chakravarthy B, Pietenpol JA (2003) Semin Oncol 30(4 Suppl 9): 23-36
    › Primary publication · 12908134 (PubMed)
  52. Cell cycle-dependent transduction of cell-permeant Cre recombinase proteins. Jo D, Lin Q, Nashabi A, Mays DJ, Unutmaz D, Pietenpol JA, Ruley HE (2003) J Cell Biochem 89(4): 674-87
    › Primary publication · 12858334 (PubMed)
  53. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. Matheny KE, Barbieri CE, Sniezek JC, Arteaga CL, Pietenpol JA (2003) Laryngoscope 113(6): 936-9
    › Primary publication · 12782800 (PubMed)
  54. Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. Coleman SC, Stewart ZA, Day TA, Netterville JL, Burkey BB, Pietenpol JA (2002) Arch Otolaryngol Head Neck Surg 128(2): 167-76
    › Primary publication · 11843726 (PubMed)
  55. Development and implementation of a science training course for breast cancer activists: Project LEAD (leadership, education and advocacy development). Dickersin K, Braun L, Mead M, Millikan R, Wu AM, Pietenpol J, Troyan S, Anderson B, Visco F (2001) Health Expect 4(4): 213-20
    › Primary publication · 11703495 (PubMed) · PMC5060083 (PubMed Central)
  56. 4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release. Ji C, Amarnath V, Pietenpol JA, Marnett LJ (2001) Chem Res Toxicol 14(8): 1090-6
    › Primary publication · 11511183 (PubMed)
  57. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, Scatena CD, Wu-Wong JR, Frost D, Sham H, Rosenberg SH, Ng SC (2001) Cancer Res 61(14): 5480-5
    › Primary publication · 11454695 (PubMed)
  58. Kinetics of p53 binding to promoter sites in vivo. Szak ST, Mays D, Pietenpol JA (2001) Mol Cell Biol 21(10): 3375-86
    › Primary publication · 11313463 (PubMed) · PMC100259 (PubMed Central)
  59. p53 Signaling and cell cycle checkpoints. Stewart ZA, Pietenpol JA (2001) Chem Res Toxicol 14(3): 243-63
    › Primary publication · 11258974 (PubMed)
  60. Syk: a new player in the field of breast cancer. Stewart ZA, Pietenpol JA (2001) Breast Cancer Res 3(1): 5-7
    › Primary publication · 11250739 (PubMed) · PMC138668 (PubMed Central)
  61. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Stewart ZA, Tang LJ, Pietenpol JA (2001) Oncogene 20(1): 113-24
    › Primary publication · 11244509 (PubMed)
  62. Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery. Flatt PM, Pietenpol JA (2000) Drug Metab Rev 32(3-4): 283-305
    › Primary publication · 11139130 (PubMed)
  63. p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Flatt PM, Polyak K, Tang LJ, Scatena CD, Westfall MD, Rubinstein LA, Yu J, Kinzler KW, Vogelstein B, Hill DE, Pietenpol JA (2000) Cancer Lett 156(1): 63-72
    › Primary publication · 10840161 (PubMed)
  64. p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA (2000) Mol Cell Biol 20(12): 4210-23
    › Primary publication · 10825186 (PubMed) · PMC85790 (PubMed Central)
  65. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Stewart ZA, Mays D, Pietenpol JA (1999) Cancer Res 59(15): 3831-7
    › Primary publication · 10447002 (PubMed)
  66. High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain. Szak ST, Pietenpol JA (1999) J Biol Chem 274(6): 3904-9
    › Primary publication · 9920946 (PubMed)
  67. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL (1999) Clin Cancer Res 5(1): 35-42
    › Primary publication · 9918200 (PubMed)
  68. p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Stewart ZA, Leach SD, Pietenpol JA (1999) Mol Cell Biol 19(1): 205-15
    › Primary publication · 9858545 (PubMed) · PMC83879 (PubMed Central)
  69. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, Pietenpol JA (1998) J Biol Chem 273(46): 30777-84
    › Primary publication · 9804855 (PubMed)
  70. Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Leach SD, Scatena CD, Keefer CJ, Goodman HA, Song SY, Yang L, Pietenpol JA (1998) Cancer Res 58(15): 3231-6
    › Primary publication · 9699647 (PubMed)
  71. Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. Flatt PM, Price JO, Shaw A, Pietenpol JA (1998) Cell Growth Differ 9(7): 535-43
    › Primary publication · 9690621 (PubMed)
  72. Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde. Ji C, Rouzer CA, Marnett LJ, Pietenpol JA (1998) Carcinogenesis 19(7): 1275-83
    › Primary publication · 9683189 (PubMed)
  73. The role of transforming growth factor beta in glioma progression. Jennings MT, Pietenpol JA (1998) J Neurooncol 36(2): 123-40
    › Primary publication · 9525812 (PubMed)
  74. Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels. Ji C, Marnett LJ, Pietenpol JA (1997) Oncogene 15(22): 2749-53
    › Primary publication · 9401002 (PubMed)
  75. Differential effects of p53 mutants on the growth of human bronchial epithelial cells. Coursen JD, Bennett WP, Khan MA, Forrester K, Pietenpol JA, Harris CC (1997) Mol Carcinog 19(3): 191-203
    › Primary publication · 9254886 (PubMed)
  76. Apoptosis of late-stage erythroblasts in megaloblastic anemia: association with DNA damage and macrocyte production. Koury MJ, Horne DW, Brown ZA, Pietenpol JA, Blount BC, Ames BN, Hard R, Koury ST (1997) Blood 89(12): 4617-23
    › Primary publication · 9192787 (PubMed)